Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...

The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...

The sale does not mean a complete exit from oncology for GSK – it will continue with programmes in immunotherapy, epigenetics, and tumour environment. The deal with Novartis includes the ...

This is a major concern for Moderna because it could mean that they used a GSK technology to produce their COVID-19 vaccine, Spikevax, as well as their RSV vaccine, mResvia. GSK asserts that ...

GSK is delivering consistent financial performance ... The Gardasil royalty loss impacted profit growth by minus 8% this quarter, meaning underlying operating profit was up 13%, demonstrating ...

On Monday, GSK plc (NYSE:GSK) released headline results ... nasal polyp score at 52 weeks and a change from baseline in mean nasal obstruction score from weeks 49 to 52. Also Read: GSK’s Asthma ...

Mean total AAT was below the level of quantification ... based on our preclinical data,” Wave CEO Paul Bolno said in a statement. GSK paid $170 million to close a deal that included global ...

GSK plc GSK announced positive data from the ... nasal polyp score at 52 weeks and the change from baseline in mean nasal obstruction score from weeks 49 to 52. Data from the studies showed ...

India's GlaxoSmithKline Pharmaceuticals reported a higher second-quarter adjusted profit on Tuesday, driven by strong demand for its generic drugs and vaccines.